Literature DB >> 22542580

FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread.

Johanna Hynninen1, Annika Auranen, Olli Carpén, Kirsti Dean, Marko Seppänen, Jukka Kemppainen, Maija Lavonius, Irina Lisinen, Johanna Virtanen, Seija Grénman.   

Abstract

OBJECTIVE: Epithelial ovarian cancer (EOC) spreads intra-abdominally and to the retroperitoneal lymph nodes. A greater number of distant metastases are revealed by (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) compared to conventional imaging methods. We aimed to investigate the presence and anatomic distribution of supradiaphragmatic lymph node metastasis (LNM) detected with pretreatment FDG PET/CT.
METHODS: Thirty women with advanced stage (IIC-IV) EOC were scanned with whole body contrast-enhanced FDG PET/CT prior to surgery/neoadjuvant chemotherapy. We performed PET/CT analysis qualitatively and quantitatively. Additionally, contrast-enhanced CT was analyzed blinded to PET/CT scan. Intra-abdominal dissemination was verified by surgery and histopathology. Metabolically active lymph nodes were biopsied when possible. The clinical characteristics of patients with and without supradiaphragmatic LNM were compared.
RESULTS: In 20/30 patients (67%) FDG PET/CT detected supradiaphragmatic LNM in one or more locations, whereas conventional CT found LNM in 10 patients (33%). Fourteen patients had parasternal, 14 cardiophrenic, 8 other mediastinal, 6 axillar, and 1 subclavian LNM. Microscopy of all four biopsied lymph nodes (three axillar and one subclavian) confirmed metastatic dissemination. The patients with supradiaphragmatic LNM had significantly more ascites (p<0.01), higher CA 125 levels, and more frequent subdiaphragmal carcinomatosis (p<0.03) compared to patients without supradiaphragmatic LNM in preoperative FDG PET/CT.
CONCLUSIONS: A significant number of patients with advanced EOC showed supradiaphragmatic LNM in pre-treatment PET/CT. Our findings suggest that the route of EOC cells from the peritoneal cavity to the lymphatic system permeates the diaphragm mainly to the cardiophrenic and continues to parasternal lymph nodes.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22542580     DOI: 10.1016/j.ygyno.2012.04.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  19 in total

1.  A rare case of mediastinal metastasis of ovarian carcinoma diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).

Authors:  Augusto Carbonari; Marco Camunha; Marcelo Binato; Mauro Saieg; Fabio Marioni; Lucio Rossini
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

Review 2.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

3.  Perimenopausal ovarian carcinoma patient with subclavian node metastasis proven by immunohistochemistry.

Authors:  Hee Jeong Jeong; Hyun Joo Kim; Eun Hee Lee; Hyoun Wook Lee; Min Kyu Kim
Journal:  J Menopausal Med       Date:  2014-04-28

4.  PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison.

Authors:  Marcelo A Queiroz; Rahel A Kubik-Huch; Nik Hauser; Bianka Freiwald-Chilla; Gustav von Schulthess; Johannes M Froehlich; Patrick Veit-Haibach
Journal:  Eur Radiol       Date:  2015-05-29       Impact factor: 5.315

Review 5.  Extra-abdominal Lymph Node Metastases as the First Presentation in Ovarian and Fallopian Tube Carcinomas.

Authors:  Maria Lúcia Moleiro; Alfredo Barroco Gouveia
Journal:  Reprod Sci       Date:  2022-08-08       Impact factor: 2.924

6.  Ovarian cancer reporting lexicon for computed tomography (CT) and magnetic resonance (MR) imaging developed by the SAR Uterine and Ovarian Cancer Disease-Focused Panel and the ESUR Female Pelvic Imaging Working Group.

Authors:  Elizabeth A Sadowski; Atul B Shinagare; Hyesun Park; Olga R Brook; Rosemarie Forstner; Sumer K Wallace; Jeanne M Horowitz; Neil Horowitz; Marcia Javitt; Priyanka Jha; Aki Kido; Yulia Lakhman; Susanna I Lee; Lucia Manganaro; Katherine E Maturen; Stephanie Nougaret; Liina Poder; Gaiane M Rauch; Caroline Reinhold; Evis Sala; Isabelle Thomassin-Naggara; Herbert Alberto Vargas; Aradhana Venkatesan; Olivera Nikolic; Andrea G Rockall
Journal:  Eur Radiol       Date:  2021-11-30       Impact factor: 7.034

7.  Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.

Authors:  Katrijn Michielsen; Ignace Vergote; Katya Op de Beeck; Frederic Amant; Karin Leunen; Philippe Moerman; Christophe Deroose; Geert Souverijns; Steven Dymarkowski; Frederik De Keyzer; Vincent Vandecaveye
Journal:  Eur Radiol       Date:  2013-12-11       Impact factor: 5.315

8.  EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA).

Authors:  Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-03       Impact factor: 9.236

9.  Trismus and diffuse polymyalgia: an unusual presentation of recurrent metastatic ovarian cancer.

Authors:  Ramsis Benjamin; Jing Zhai; Robert Morgan; Neal Prakash
Journal:  BMJ Case Rep       Date:  2014-05-16

10.  18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer.

Authors:  Tuulia Vallius; Johanna Hynninen; Jukka Kemppainen; Victor Alves; Kari Auranen; Jaakko Matomäki; Sinikka Oksa; Johanna Virtanen; Seija Grénman; Annika Auranen; Marko Seppänen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-23       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.